肝癌相关肿瘤抗原HLA-A2限制性CTL表位的预测  

Prediction of HLA-A2-restricted CTL epitope derived from tumor antigens associated with hepatocellular carcinoma

作　　者：董海龙[1] 隋延仿[1] 

机构地区：[1]第四军医大学基础部病理学教研室,陕西西安710033

出　　处：《第四军医大学学报》2003年第6期492-494,共3页Journal of the Fourth Military Medical University

基　　金：国家自然科学基金重点资助项目 (39830 4 2 0 )

摘　　要：目的 :预测肝癌肿瘤抗原的HLA A2限制性CTL表位 .方法 :选择与肝癌相关的肿瘤抗原MAGE 1,MAGE 3 ,MAGE 8,p5 3及AFP为研究目标 ,采用SYFPEITHI基序法远程预测系统和量化基序多项式法结合的预测方法进行HLA A 0 2 0 1限制性CTL表位预测 .结果 :共预测出与肝癌相关的肿瘤相关抗原的 3 5个HLA A2限制性CTL表位 .结论 :两种预测方法结果的一致性较好 ,所预测的 3 5个肿瘤抗原HLA A2限制性CTL表位经实验筛选、鉴定后 ,可望用于新型肝癌治疗性多肽疫苗的设计研究 。AIM: To predict the HLA A2 restricted CTL epitopes of tumor antigens associated with hepatocellular carcinoma (HCC). METHODS: The CTL epitopes of tumro antigen associated with HCC (MAGE 1, MAGE 3, MAGE 8, p53 and AFP) were predicted by HLA A*0201 binding peptide SYFPEITHI prediction method combined with the polynomial method. RESULTS: Thirty five HLA A2 restricted CTL epitope candidates (nonamers) derived from the tumor antigen associated with HCC were selected. CONCLUSION: The combination of SYFPEITHI prediction method and polynomial method can improve the prediction efficiency and accuracy. These nonamers, selected and identified by experiment, may be useful in the design of therapeutic peptides vaccine for HCC.

关 键 词：抗原 肝细胞肿瘤 肝细胞癌 HLA-A2抗原 T淋巴细胞 细胞毒性 表位 

分 类 号：R735.7[医药卫生—肿瘤]